Intratumoral gene therapy of malignant brain tumor in a rat model with angiostatin delivered by adeno-associated viral (AAV) vector

H. I. Ma, S. Z. Lin, Y. H. Chiang, J. Li, S. L. Chen, Y. P. Tsao, X. Xiao

Research output: Contribution to journalArticle

82 Citations (Scopus)

Abstract

We have utilized a recombinant adeno-associated viral (AAV) vector carrying the angiostatin gene as an anti-angiogenesis strategy to treat the malignant brain tumor in a C6 glioma/Wistar rat model. Angiostatin, as a potent angiogenesis inhibitor, shows high promises as an anti-cancer drug through the inhibition of tumor neovessel formation. However, sustained in vivo protein delivery is required to achieve the therapeutic effects. The AAV vector has been proven to be able to deliver sustained and high-level gene expression in vivo, and therefore, is well suited to such a purpose. In this study, we implanted 5 × 105 C6 glioma cells into the rat brain 7 days before gene therapy. Intratumoral injection of a high-titer AAV-angiostatin vector has rendered efficacious tumor suppression and resulted in long-term survival in 40% of the treated rats, whereas the control AAV-GFP vector did not have any therapeutic benefits. In addition, we have investigated the combined gene therapy of an adenoviral vector carrying the suicidal thymidine kinase gene along with the AAV-angiostatin vector. The combined therapy offered the best tumor-suppressive effects and increased long-term survival to 55% in the treated rats. Our study has demonstrated the potential of using AAV as a safe and effective vector for anti-angiogenic gene therapy of brain tumors.

Original languageEnglish
Pages (from-to)2-11
Number of pages10
JournalGene Therapy
Volume9
Issue number1
DOIs
Publication statusPublished - 2002
Externally publishedYes

Fingerprint

Angiostatins
Brain Neoplasms
Genetic Therapy
Glioma
Neoplasms
Angiogenesis Inhibitors
Thymidine Kinase
Therapeutic Uses
Genes
Wistar Rats
Gene Expression
Injections
Brain
Therapeutics
Pharmaceutical Preparations
Proteins

Keywords

  • Adeno-associated viral (AAV) vector
  • Angiostatin gene
  • Antiangiogenesis
  • C6 glioma cells
  • Gene therapy

ASJC Scopus subject areas

  • Genetics

Cite this

Intratumoral gene therapy of malignant brain tumor in a rat model with angiostatin delivered by adeno-associated viral (AAV) vector. / Ma, H. I.; Lin, S. Z.; Chiang, Y. H.; Li, J.; Chen, S. L.; Tsao, Y. P.; Xiao, X.

In: Gene Therapy, Vol. 9, No. 1, 2002, p. 2-11.

Research output: Contribution to journalArticle

Ma, H. I. ; Lin, S. Z. ; Chiang, Y. H. ; Li, J. ; Chen, S. L. ; Tsao, Y. P. ; Xiao, X. / Intratumoral gene therapy of malignant brain tumor in a rat model with angiostatin delivered by adeno-associated viral (AAV) vector. In: Gene Therapy. 2002 ; Vol. 9, No. 1. pp. 2-11.
@article{41ece0de5a324dd4bc631bb2d80c2a79,
title = "Intratumoral gene therapy of malignant brain tumor in a rat model with angiostatin delivered by adeno-associated viral (AAV) vector",
abstract = "We have utilized a recombinant adeno-associated viral (AAV) vector carrying the angiostatin gene as an anti-angiogenesis strategy to treat the malignant brain tumor in a C6 glioma/Wistar rat model. Angiostatin, as a potent angiogenesis inhibitor, shows high promises as an anti-cancer drug through the inhibition of tumor neovessel formation. However, sustained in vivo protein delivery is required to achieve the therapeutic effects. The AAV vector has been proven to be able to deliver sustained and high-level gene expression in vivo, and therefore, is well suited to such a purpose. In this study, we implanted 5 × 105 C6 glioma cells into the rat brain 7 days before gene therapy. Intratumoral injection of a high-titer AAV-angiostatin vector has rendered efficacious tumor suppression and resulted in long-term survival in 40{\%} of the treated rats, whereas the control AAV-GFP vector did not have any therapeutic benefits. In addition, we have investigated the combined gene therapy of an adenoviral vector carrying the suicidal thymidine kinase gene along with the AAV-angiostatin vector. The combined therapy offered the best tumor-suppressive effects and increased long-term survival to 55{\%} in the treated rats. Our study has demonstrated the potential of using AAV as a safe and effective vector for anti-angiogenic gene therapy of brain tumors.",
keywords = "Adeno-associated viral (AAV) vector, Angiostatin gene, Antiangiogenesis, C6 glioma cells, Gene therapy",
author = "Ma, {H. I.} and Lin, {S. Z.} and Chiang, {Y. H.} and J. Li and Chen, {S. L.} and Tsao, {Y. P.} and X. Xiao",
year = "2002",
doi = "10.1038/sj/gt/3301616",
language = "English",
volume = "9",
pages = "2--11",
journal = "Gene Therapy",
issn = "0969-7128",
publisher = "Nature Publishing Group",
number = "1",

}

TY - JOUR

T1 - Intratumoral gene therapy of malignant brain tumor in a rat model with angiostatin delivered by adeno-associated viral (AAV) vector

AU - Ma, H. I.

AU - Lin, S. Z.

AU - Chiang, Y. H.

AU - Li, J.

AU - Chen, S. L.

AU - Tsao, Y. P.

AU - Xiao, X.

PY - 2002

Y1 - 2002

N2 - We have utilized a recombinant adeno-associated viral (AAV) vector carrying the angiostatin gene as an anti-angiogenesis strategy to treat the malignant brain tumor in a C6 glioma/Wistar rat model. Angiostatin, as a potent angiogenesis inhibitor, shows high promises as an anti-cancer drug through the inhibition of tumor neovessel formation. However, sustained in vivo protein delivery is required to achieve the therapeutic effects. The AAV vector has been proven to be able to deliver sustained and high-level gene expression in vivo, and therefore, is well suited to such a purpose. In this study, we implanted 5 × 105 C6 glioma cells into the rat brain 7 days before gene therapy. Intratumoral injection of a high-titer AAV-angiostatin vector has rendered efficacious tumor suppression and resulted in long-term survival in 40% of the treated rats, whereas the control AAV-GFP vector did not have any therapeutic benefits. In addition, we have investigated the combined gene therapy of an adenoviral vector carrying the suicidal thymidine kinase gene along with the AAV-angiostatin vector. The combined therapy offered the best tumor-suppressive effects and increased long-term survival to 55% in the treated rats. Our study has demonstrated the potential of using AAV as a safe and effective vector for anti-angiogenic gene therapy of brain tumors.

AB - We have utilized a recombinant adeno-associated viral (AAV) vector carrying the angiostatin gene as an anti-angiogenesis strategy to treat the malignant brain tumor in a C6 glioma/Wistar rat model. Angiostatin, as a potent angiogenesis inhibitor, shows high promises as an anti-cancer drug through the inhibition of tumor neovessel formation. However, sustained in vivo protein delivery is required to achieve the therapeutic effects. The AAV vector has been proven to be able to deliver sustained and high-level gene expression in vivo, and therefore, is well suited to such a purpose. In this study, we implanted 5 × 105 C6 glioma cells into the rat brain 7 days before gene therapy. Intratumoral injection of a high-titer AAV-angiostatin vector has rendered efficacious tumor suppression and resulted in long-term survival in 40% of the treated rats, whereas the control AAV-GFP vector did not have any therapeutic benefits. In addition, we have investigated the combined gene therapy of an adenoviral vector carrying the suicidal thymidine kinase gene along with the AAV-angiostatin vector. The combined therapy offered the best tumor-suppressive effects and increased long-term survival to 55% in the treated rats. Our study has demonstrated the potential of using AAV as a safe and effective vector for anti-angiogenic gene therapy of brain tumors.

KW - Adeno-associated viral (AAV) vector

KW - Angiostatin gene

KW - Antiangiogenesis

KW - C6 glioma cells

KW - Gene therapy

UR - http://www.scopus.com/inward/record.url?scp=0036167266&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0036167266&partnerID=8YFLogxK

U2 - 10.1038/sj/gt/3301616

DO - 10.1038/sj/gt/3301616

M3 - Article

C2 - 11850717

VL - 9

SP - 2

EP - 11

JO - Gene Therapy

JF - Gene Therapy

SN - 0969-7128

IS - 1

ER -